First day of the ‘II EAS Multidisciplinary Symposium’ in Madrid.
More than 260 specialists from all over the country are meeting today in Madrid at the ‘II Multidisciplinary Symposium on Systemic Autoimmune Diseases (EAS)’ with the aim of analyze the main diagnostic and therapeutic novelties in this field under a integrative approach and to pool scientific knowledge on advances in the diagnosis and treatment of these pathologies, as the participating medical societies have highlighted in a joint press release.
“EAS make up a wide group of little-known pathologies by the population and, despite the fact that their exact origin is unknown, it is known that they all share a failure of the immune system, which stops doing its job properly, defending us from external aggressions, and begins to cause damage to the tissues themselves and cells,” the statement stressed.
They add that virtually “any organ” can be seen affectedincluding the joints, muscles, skin, and also vital organs such as the brain, heart, kidneys or lungs, and that is why they can lead to serious clinical situations with high mortality.
its unknown etiopathogenesisalthough they are considered to be diseases that have a genetic predisposition and that are activated following an external trigger (environmental pollutantinfection, etc.) or even an internal trigger (hormone imbalance, etc.). Being systemic diseases, they can simultaneously affect more than one organ at the same time, which complicates the already diagnostic and therapeutic complexity characteristic of these diseases. The interdisciplinary and multidisciplinary management of EAS, therefore, “is not only necessary, but also crucial and essential”, they point out.
Global incidence of autoimmune diseases
It is estimated that the prevalence of autoimmune diseases globally it is 3 to 5 percent. Of this percentage, it is estimated that 80 percent of the people who suffer from any of these pathologies are women. Among the EAS, the most frequent are Sjögren’s syndrome, Systemic Lupus Erythematosus, Sarcoidosis and Antiphospholipid Syndrome. The rest of EAS have a prevalence less than 1 case per 2,000 people Therefore, they are classified as rare diseases, among which would be included, among others, the systemic sclerosisinflammatory myopathies and systemic vasculitis.
This Friday there will be different sessions focused on lupussarcoidosis, systemic sclerosisvaccination in patients with immunodeficiencies, Antiphospholipid Syndrome, Sjögren’s or vasculitis. For its part, on Saturday the scientific activity will focus on inflammatory myopathiesautoinflammatory diseases, therapeutic novelties and Behçet’s disease.
The second edition of this symposium is organized by the Spanish Society of Internal Medicine (SEMI) jointly with the Spanish Academy of Dermatology and Venereology (AEDV), the Spanish Society of Immunology (BE), the Spanish Society of Nephrology (SEN), the Spanish Society of Pneumology and Thoracic Surgery (Separ), the Spanish Society of Rheumatology (TO BE) and the Spanish Society of Digestive Pathology (SEPD).
Said symposium has an “innovative” format and a multidisciplinary scientific program made up of 11 tables in which More than thirty renowned speakers participate of each specialty and includes various topics on research and management of these pathologies, placing the patient at the center, as emphasized by medical societies.
The need to work in a multidisciplinary way
Given the complexity of SAEs and the multi-organ damage that they can cause, it is “essential” that the management of these patients be carried out accordingly. jointly from different specialties. In the words of the organizers, “I am sure that this second edition of the symposium will consolidate multidisciplinary work from which we all benefit, doctors and, above all, patients with EAS”.
Some of the main novelties of the second edition of the symposium include the presentation of the document of consensus on the treatment of lupus nephropathyas well as others such as the response to vaccines in patients with immunodeficiencies and in patients with advanced chronic kidney disease, description of a new monogenic disease, Vexas syndrome, novelties in autoinflammatory diseases and autoimmune digestive manifestations of checkpoint inhibitor drugs.
In addition, there will be a section for competitions for complex clinical cases (with more than 70 cases), and it will delve into new antibodies that are associated with manifestations on the border between the Antiphospholipid Syndrome and other pathologies that are not well characterized, but where there may be a not well-defined vascular component.
It will also delve into small vessel vasculitis mediated by immune complexes and neutrophilic dermatoses, how to treat complex lupus or what to do in the event of sarcoidosis refractory to corticosteroids or how to deal with a catastrophic APS or refractory Behçet’s disease, as well as pulmonary involvement in Sjögren’s, in ANCA-vasculitis and in Sarcoidosis. It will also address kidney involvement in various systemic diseases and new developments in their management and treatment.
The information published in Redacción Médica contains affirmations, data and statements from official institutions and health professionals. However, if you have any questions related to your health, consult your corresponding health specialist.
